Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Status: | Recruiting |
---|---|
Conditions: | Lymphoma |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/27/2019 |
Start Date: | January 24, 2014 |
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when
given together with brentuximab vedotin, and how well they work in treating patients with
Hodgkin lymphoma that has returned after a period of improvement or has not responded to
previous treatment. Immunotherapy with monoclonal antibodies, such as ipilimumab and
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal
antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells
called cluster of differentiation (CD)30 and may kill the cells. It is not known whether
giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer
cells.
given together with brentuximab vedotin, and how well they work in treating patients with
Hodgkin lymphoma that has returned after a period of improvement or has not responded to
previous treatment. Immunotherapy with monoclonal antibodies, such as ipilimumab and
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal
antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells
called cluster of differentiation (CD)30 and may kill the cells. It is not known whether
giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer
cells.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the
combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and
brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete
response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to
brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response
rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin
and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate
the duration of remission (DOR) to these combinations and compare with the DOR achieved with
the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free
survival (PFS) and the overall survival (OS) in patients receiving the combination of
brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab
vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease
(SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin,
ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and
compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To
evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin
and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further
evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin
and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
CORRELATIVE STUDY OBJECTIVES:
I. To evaluate the ability of these combinations to alter tumor specific T cell immunity.
(Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I)
III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood
as a potential immune signature of treatment response to therapy with these combinations for
patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene
expression profiling (GEP) a signature of response to these novel combinations of an antibody
drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these
combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in
patients as a function of treatment response at multiple timepoints during therapy. (Phase
II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients
at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of
response versus (vs.) resistance to these novel combinations of an antibody drug conjugate
with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut
microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)
IMAGING CORRELATIVE STUDY OBJECTIVES:
I. To evaluate atypical response patterns with currently available response evaluation
criteria. (Phase II) II. To correlate response evaluated using currently available response
evaluation criteria with duration of response (PFS, event free survival [EFS], failure free
survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy
treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To
correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and
nivolumab followed by a phase II study.
PHASE I: Patients are assigned into 1 of 3 arms.
ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 and
ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every
21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and
nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up
to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of
disease progression or unacceptable toxicity.
ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16,
nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on
day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles
and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease
progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and
nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up
to 34 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16,
nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on
day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles
in the absence of disease progression or unacceptable toxicity.
After completion of phase I study treatment, patients are followed up every 3 months for 1
year, then every 6 months for 2 years. After completion of phase II study treatment, patients
are followed up for 5 years.
I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the
combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and
brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete
response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to
brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response
rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin
and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate
the duration of remission (DOR) to these combinations and compare with the DOR achieved with
the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free
survival (PFS) and the overall survival (OS) in patients receiving the combination of
brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab
vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease
(SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin,
ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and
compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To
evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin
and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further
evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin
and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
CORRELATIVE STUDY OBJECTIVES:
I. To evaluate the ability of these combinations to alter tumor specific T cell immunity.
(Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I)
III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood
as a potential immune signature of treatment response to therapy with these combinations for
patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene
expression profiling (GEP) a signature of response to these novel combinations of an antibody
drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these
combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in
patients as a function of treatment response at multiple timepoints during therapy. (Phase
II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients
at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of
response versus (vs.) resistance to these novel combinations of an antibody drug conjugate
with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut
microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)
IMAGING CORRELATIVE STUDY OBJECTIVES:
I. To evaluate atypical response patterns with currently available response evaluation
criteria. (Phase II) II. To correlate response evaluated using currently available response
evaluation criteria with duration of response (PFS, event free survival [EFS], failure free
survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy
treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To
correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and
nivolumab followed by a phase II study.
PHASE I: Patients are assigned into 1 of 3 arms.
ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 and
ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every
21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and
nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up
to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of
disease progression or unacceptable toxicity.
ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16,
nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on
day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles
and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease
progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and
nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up
to 34 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16,
nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on
day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles
in the absence of disease progression or unacceptable toxicity.
After completion of phase I study treatment, patients are followed up every 3 months for 1
year, then every 6 months for 2 years. After completion of phase II study treatment, patients
are followed up for 5 years.
Inclusion Criteria:
- PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)
- Patients must have pathologically confirmed relapsed or refractory classical Hodgkin
lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including
lymphocyte predominant (LP) HL are not permitted
- Patients must have relapsed after first line chemotherapy; may have relapsed after
autologous or allogeneic stem cell transplant, or have primary refractory disease; no
upper limit for number of prior therapies; if status post allogeneic stem cell
transplant, no active graft versus host disease
- Patients may have received prior brentuximab vedotin, but must not have received
brentuximab vedotin within 6 months prior to registration, and must not have relapsed
within 6 months of receiving previous brentuximab vedotin; patients may not have
received prior nivolumab or PD1/PDL1 axis agents; patients in the
nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab
- Patients may have received other prior activating immunotherapies (i.e. checkpoint
inhibitors), but must not have received them within 6 months prior to registration,
and there must be no serious unresolved complication of therapy at the time of
registration; for the purposes of this study monoclonal antibodies and antibody drug
conjugates are not considered to be activating immunotherapies and there are no
additional time restrictions on prior exposure to these agents (except prior
brentuximab vedotin)
- Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging
Network (ACRIN) performance status between 0-2
- Patients must have measurable disease; baseline measurements and evaluations must be
obtained within 4 weeks of registration to the study; abnormal positron emission
tomography (PET) scans will not constitute evaluable disease unless verified by a
diagnostic quality computed tomography (CT) scan; patients must use the same imaging
modality (CT or PET/CT) throughout the study
- Women must not be pregnant or breast-feeding due to risk of fetal harm by the
chemotherapeutic agents prescribed in this protocol; all females of childbearing
potential must have a blood test or urine study within 2 weeks prior to registration
to rule out pregnancy; a female of childbearing potential is any woman, regardless of
sexual orientation or whether they have undergone tubal ligation, who meets the
following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or
2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has
had menses at any time in the preceding 24 consecutive months)
- Women of childbearing potential (WOCBP) and sexually active males must either abstain
from sexual intercourse for the duration of their participation in the study or agree
to use both double barrier contraception and birth control pills or implants for at
least one week prior to the start of the study drug and continuing for 5 months after
the last dose of study drug (for female patients) and for 7 months after the last dose
of study drug (for male patients who are sexually active with WOCBP); should a woman
become pregnant or suspect she is pregnant while she or her partner is participating
in this study, she (or the participating partner) should inform the treating physician
immediately
- Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while
breathing room air
- Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity
(FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass
from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted
value; all pulmonary function tests must be obtained within one month prior to
registration
- Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks
prior to registration)
- Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit
of normal (ULN) (obtained within 2 weeks prior to registration)
- Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome,
for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within
2 weeks prior to registration)
- Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained
within 2 weeks prior to registration)
- No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in
situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously
disease free for >= 5 years so as not to interfere with interpretation of radiographic
response
- Patient must have no current or prior history of central nervous system (CNS)
involvement
- All prior therapy must have been completed at least 21 days prior to enrollment; no
concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose
of treatment of lymphoma are allowed; topical steroids are allowed
- No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome,
or motor neuropathy
- Human immunodeficiency virus (HIV) positive patients are allowed on this study if they
have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly
controlled HIV or other chronic active viral infections will be excluded
- Patients must not have autoimmune disorders or conditions of immunosuppression that
require current ongoing treatment with systemic corticosteroids (or other systemic
immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or
continuous use of topical steroid creams or ointments or ophthalmologic steroids; a
history of occasional (but not continuous) use of steroid inhalers is allowed
- Replacement doses of steroids for patients with adrenal insufficiency are
allowed; patients who discontinue use of these classes of medication for at least
2 weeks prior to initiation of study treatment are eligible if, in the judgment
of the treating physician investigator, the patient is not likely to require
resumption of treatment with these classes of drugs during the study
- Exclusion from this study also includes patients with a history of symptomatic
autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis
[scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune
vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of
autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other
CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune
hypothyroid disease or type I diabetes on replacement treatment are eligible
- Patients must not have grade 2 or greater peripheral sensory neuropathy
- Patients must not have New York Heart Association (NYHA) class III or IV heart
failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
electrocardiographic evidence of acute ischemia
- Patients must not have previously existing hypersensitivity to brentuximab vedotin or
ipilimumab
- Patients must not have a serious medical or psychiatric illness likely to interfere
with study participation
- Patients must not be participating in any other clinical trial or taking any other
experimental medications within 21 days prior to registration
- Routine vaccinations, including seasonal influenza, should be given at least 2 weeks
prior to study treatment; vaccines are not prohibited on study, but must be given at
least 6 weeks after cycle 1 and not within 7 days of treatment
- Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking
tobacco or other substances and must not have smoked within the past 6 months
- RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed
relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is
acceptable; other histologies including lymphocyte predominant (LP) HL are not
permitted
- RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line
chemotherapy; may have relapsed after autologous stem cell transplant, or have primary
refractory disease; no upper limit for number of prior therapies; patient must not
have received a prior allogeneic stem cell transplant
- RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab
vedotin, but must not have received brentuximab vedotin within 6 months prior to
registration, and must not have relapsed within 6 months of receiving previous
brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis
agents; patients may not have received prior ipilimumab
- RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior
activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of
this study monoclonal antibodies and antibody drug conjugates are not considered to be
activating immunotherapies and there are no additional time restrictions on prior
exposure to these agents (except prior brentuximab vedotin)
- RANDOMIZED PHASE II (ARMS K AND L): ECOG-ACRIN performance status between 0-2
- RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline
measurements and evaluations must be obtained within 4 weeks of registration to the
study; abnormal PET scans will not constitute evaluable disease unless verified by a
diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT)
throughout the study
- RANDOMIZED PHASE II (ARMS K AND L): Women must not be pregnant or breast-feeding due
to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all
females of childbearing potential must have a blood test or urine study within 24
hours prior to enrollment to rule out pregnancy; a female of childbearing potential is
any woman, regardless of sexual orientation or whether they have undergone tubal
ligation, who meets the following criteria: 1) has not undergone a hysterectomy or
bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24
consecutive months (i.e., has had menses at any time in the preceding 24 consecutive
months)
- RANDOMIZED PHASE II (ARMS K AND L): Women of childbearing potential (WOCBP) and
sexually active males must either abstain from sexual intercourse for the duration of
their participation in the study or agree to use both double barrier contraception and
birth control pills or implants for at least one week prior to the start of the study
drug and continuing for 5 months after the last dose of study drug (for female
patients) and for 7 months after the last dose of study drug (for male patients who
are sexually active with WOCBP); should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she (or the
participating partner) should inform the treating physician immediately
- RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest
and a pulse oximetry > 92% while breathing room air
- RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary
function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide
diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary
function tests must be obtained within one month prior to registration
- RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2
weeks prior to registration)
- RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained
within 2 weeks prior to registration)
- RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN)
(obtained within 2 weeks prior to registration)
- RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN)
(unless documented Gilbert's syndrome, for which Bilirubin =< 3 x upper limit of
normal [ULN] is permitted) (obtained within 2 weeks prior to registration)
- RANDOMIZED PHASE II (ARMS K AND L): Calculated creatinine clearance by Cockroft-Gault
formula >= 30 ml/min (obtained within 2 weeks prior to registration)
- RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately
treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or
radiation-cured malignancy continuously disease free for >= 5 years so as not to
interfere with interpretation of radiographic response
- RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of
CNS involvement
- RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at
least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no
concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose
of treatment of lymphoma are allowed; topical steroids are allowed
- RANDOMIZED PHASE II (ARMS K AND L): No history of Steven's Johnson's syndrome, TENs
syndrome, or motor neuropathy
- RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they
meet the other protocol criteria including the following:
- Long term survival expected were it not for the cHL
- HIV viral loads undetectable by standard clinical HIV testing
- Willing to adhere to effective combination antiretroviral therapy
- RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders or
conditions of immunosuppression that require current ongoing treatment with systemic
corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e.,
prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or
ophthalmologic steroids; a history of occasional (but not continuous) use of steroid
inhalers is allowed; replacement doses of steroids for patients with adrenal
insufficiency are allowed; patients who discontinue use of steroid medication for at
least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the
treating physician investigator, the patient is not likely to require resumption of
treatment with these classes of drugs during the study; exclusion from this study also
includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid
arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus,
Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor
neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and
Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients
with autoimmune hypothyroid disease or type I diabetes on replacement treatment are
eligible
- RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater
peripheral sensory ne
We found this trial at
355
sites
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
800 Washington St
Boston, Massachusetts 02111
Boston, Massachusetts 02111
(617) 636-5000
![Tufts Medical Center](/wp-content/uploads/logos/tufts-medical-center.jpg)
Principal Investigator: Andrew M. Evens
Phone: 617-636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
![University Medical Center of Southern Nevada](/wp-content/uploads/logos/university-medical-center-of-southern-nevada.jpg)
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
![Providence Portland Medical Center](/wp-content/uploads/logos/providence-portland-medical-center.png)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Atlanta, Georgia 30322
Principal Investigator: Jonathon B. Cohen
Phone: 404-778-1868
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
![Rush - Copley Medical Center](/wp-content/uploads/logos/rush---copley-medical-center.png)
Principal Investigator: Suparna Mantha
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baltimore, Maryland 21229
Principal Investigator: Carole B. Miller
Phone: 410-368-2910
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
![Johns Hopkins University-Sidney Kimmel Cancer Center](/wp-content/uploads/logos/johns-hopkins-university-sidney-kimmel-cancer-center.png)
Principal Investigator: Richard F. Ambinder
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
![Saint Vincent Healthcare](/wp-content/uploads/logos/saint-vincent-healthcare.png)
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Birmingham, Alabama 35233
Principal Investigator: Amitkumar N. Mehta
Phone: 205-934-0220
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
![Illinois CancerCare-Bloomington](/wp-content/uploads/logos/illinois-cancercare-bloomington.gif)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
![Saint Luke's Mountain States Tumor Institute](/wp-content/uploads/logos/saint-luke-s-mountain-states-tumor-institute.gif)
Principal Investigator: Alison K. Conlin
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
![Boulder Community Hospital](/wp-content/uploads/logos/boulder-community-hospital.jpg)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
![Bozeman Deaconess Hospital](/wp-content/uploads/logos/bozeman-deaconess-hospital.jpg)
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bridgeport, West Virginia 26330
Principal Investigator: Lauren W. Veltri
Phone: 304-293-7374
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burlington, Wisconsin 53105
Principal Investigator: Michael A. Thompson
Phone: 414-302-2304
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
![Saint James Community Hospital and Cancer Treatment Center](/wp-content/uploads/logos/saint-james-community-hospital-and-cancer-treatment-center.png)
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
![Illinois CancerCare - Canton](/wp-content/uploads/logos/illinois-cancercare---canton.jpg)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
![Saint Francis Medical Center](/wp-content/uploads/logos/saint-francis-medical-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
![Southeast Cancer Center](/wp-content/uploads/logos/southeast-cancer-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
![Illinois CancerCare - Carthage](/wp-content/uploads/logos/illinois-cancercare---carthage.jpg)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Chapel Hill, North Carolina 27599
Principal Investigator: Anne W. Beaven
Phone: 877-668-0683
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Chattanooga, Tennessee 37404
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
![Rush University Medical Center](/wp-content/uploads/logos/rush-university-medical-center.jpg)
Principal Investigator: Parameswaran Venugopal
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Leo I. Gordon
Phone: 312-695-1301
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
![Clackamas Radiation Oncology Center](/wp-content/uploads/logos/clackamas-radiation-oncology-center.jpg)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Clackamas, Oregon 97015
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2500 Metrohealth Dr
Cleveland, Ohio 44109
Cleveland, Ohio 44109
(216) 778-7800
![MetroHealth Med Ctr](/wp-content/uploads/logos/metrohealth-med-ctr.jpg)
Principal Investigator: Bruce J. Averbook
Phone: 216-778-8526
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
![Mercy Cancer Center - West Lakes](/wp-content/uploads/logos/mercy-cancer-center---west-lakes.jpg)
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Colorado Springs, Colorado 80907
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Coos Bay, Oregon 97420
Principal Investigator: Alison K. Conlin
Phone: 541-269-8392
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Corbin, Kentucky 40701
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Council Bluffs, Iowa 51503
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1203 South Tyler Street
Covington, Louisiana 70433
Covington, Louisiana 70433
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Creston, Iowa 50801
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Neha Mehta-Shah
Phone: 800-600-3606
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Danville, Illinois 61832
Principal Investigator: Suparna Mantha
Phone: 800-446-5532
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
![Decatur Memorial Hospital](/wp-content/uploads/logos/decatur-memorial-hospital.jpg)
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
115 10th Avenue Northeast
Deer River, Minnesota 56636
Deer River, Minnesota 56636
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
777 Bannock St
Denver, Colorado 80204
Denver, Colorado 80204
(303) 436-6000
![Denver Health Medical Center](/wp-content/uploads/logos/denver-health-medical-center.jpg)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4567 E 9th Ave
Denver, Colorado 80220
Denver, Colorado 80220
(303) 320-2121
![Rose Medical Center](/wp-content/uploads/logos/rose-medical-center.jpg)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Rose Medical Center Well known as a Denver institution and a 9th Avenue landmark for...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2525 S Downing St
Denver, Colorado 80210
Denver, Colorado 80210
(303) 778-1955
![Porter Adventist Hospital](/wp-content/uploads/logos/porter-adventist-hospital.jpg)
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Porter Adventist Hospital Founded in 1930, Porter Adventist Hospital has provided people throughout Denver and...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
Denver, Colorado 80218
720-754-4800
![Colorado Blood Cancer Institute](/wp-content/uploads/logos/colorado-blood-cancer-institute.png)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Denver, Colorado 80220
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Denver, Colorado 80218
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Denver, Colorado 80206
Principal Investigator: Keren Sturtz
Phone: 877-225-5654
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)